Has the time come for the reduction of ischemic heart disease through influencing Lp(a) levels?
Authors:
Ján Murín
Authors‘ workplace:
I. interná klinika LFUK a UNB, Nemocnica Staré Mesto, Bratislava
Published in:
Forum Diab 2017; 6(1): 39-41
Category:
Overview
Some genomic analyses have shown that LPA gene is associated with plasma concentration of Lp(a) which, in turn, is considered to be a causal risk factor for ischemic heart disease (ICHS). And it may be expected that the reduction of serum concentration of Lp(a) can favourably influence the development of ICHS. A meta-analysis of data from three databases (UK Biobank, CARDIOGRAM, MIGen, altogether 248,164 individuals) regarding the relation of Lp(a) serum reduction, by one standard deviation, to multiple cardiovascular diseases, has identified the reduction of the risk for ICHS by 29% , for peripheral arterial disease by 31% and stroke by 13% (all statistically relevant). That is, the reduction of serum Lp(a) as a result of LPA gene (the gene for Lp(a)) behaviour significantly affects the occurrence of cardiovascular diseases. We can assume that the effective therapeutic reduction of serum Lp(a) will bring about a cardiovascular benefit.
Key words:
cardiovascular diseasesserum, lipoprotein (a) Lp(a), serum Lp(a) reduction
Received:
14. 3. 2017
Accepted:
24. 3. 2017
Sources
1. Gaziano TA, Prabhakaran D, Gaziano JM, Global burden of cardiovascular disease. In: Mann DL et al. Braunwald’s Heart Disease. 10th ed. Elsevier Canada 2015: 1–20. ISBN: 978–1-4557–5133–4.
2. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012; 60(8): 716–721.
3. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302(4): 412–423.
4. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26): 2518–2528.
5. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301(22): 2331–2339.
6. Tsimikas S, Viney NJ, Hughes SG et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386(10002):1472–1483.
7. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013; 12(8): 581–594.
8. Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368(6): 503–512.
9. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 63(5):470–477.
10. Sawabe M, Tanaka N, Mieno MN et al. Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: population-based cohort study (the JMS cohort study). PLoS ONE 2012;7:e31954. Dostupné z DOI: <http://doi:10.1371/journal.pone.0031954>.
11. Mora S, Kamstrup PR, Rifai N et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56(8): 1252–1260.
12. Endim CA, Khea AV, Natarajan P et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol 2016; 68(25): 2761–2772.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2017 Issue 1
Most read in this issue
- Angio OCT – a new non-invasive imaging examination method of diagnosing and monitoring of diabetic retinopathy
- Metabolic diseases and the eye in childhood
- Auto-immunity and diabetes mellitus
- Diabetes mellitus and skin disorders